We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 6.50 | 0.41% | 1,590.00 | 1,589.50 | 1,590.50 | 1,590.00 | 1,575.00 | 1,579.50 | 1,164,571 | 14:47:13 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.24 | 65.23B |
From Apr 2019 to Apr 2024
TIDMGSK
RNS Number : 6498U
GlaxoSmithKline PLC
13 July 2018
GlaxoSmithKline plc (the 'Company')
Transaction notification
Hot Features
Premium
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Ms E Walmsley
=== ======================== ============================================
b) Position/status Chief Executive Officer
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.7040 16
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2018-07-12
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mr R G Connor
=== ======================== ============================================
b) Position/status President, Global Manufacturing & Supply
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.7040 59
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2018-07-12
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mr S Dingemans
=== ======================== ============================================
b) Position/status Chief Financial Officer
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.7040 21
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2018-07-12
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mr N Hirons
=== ======================== ============================================
b) Position/status SVP, Global Ethics & Compliance
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.7040 10
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2018-07-12
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mr L Miels
=== ======================== ============================================
b) Position/status President, Global Pharmaceuticals
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.7040 1
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2018-07-12
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mr D S Redfern
=== ======================== ============================================
b) Position/status Chief Strategy Officer
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.7040 68
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2018-07-12
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Ms C Thomas
=== ======================== ============================================
b) Position/status SVP, Human Resources
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.7040 68
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2018-07-12
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mr P C Thomson
=== ======================== ============================================
b) Position/status President, Global Affairs
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.7040 38
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2018-07-12
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mrs V A Whyte
=== ======================== ============================================
b) Position/status Company Secretary
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.7040 49
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2018-07-12
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHEXLFFVDFFBBL
(END) Dow Jones Newswires
July 13, 2018 11:16 ET (15:16 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
